Selvita S.A. has received permission from the President of the City of Krakow to build a Research and Development Centre for Laboratory Services in the area of drug discovery and development. The centre is expected to be ready by the end of 2022. Launch of the Selvita Laboratory Services Centre The Laboratory Services Centre will…
Selvita, which specialises in laboratory research and development services for external customers, has announced the conclusion of its first acquisition agreement. The Polish company will acquire 100% of shares in a Croatian company operating on the contract research market in the pre-clinical area. However, certain conditions must be met beforehand. Fidelta in Selvita’s structure in…
The company’s new strategy for 2020-2023 assumes a three-fold increase in revenues. This will be achieved through acquisitions and organic growth. Boguslaw Sieczkowski, President of Selvita, emphasises that the Laboratory Services Centre will be built in Krakow on his own plot. New strategy and planned acquisitions In the years 2020-2023, Selvita intends to allocate PLN…
Selvita, which specialises in laboratory research and development services for external customers, wants to increase the scale of its operations in the near future. This will be achieved, among other things, through acquisitions. The first transaction is to be finalised in 2020, Puls Biznesu reports. Purchase of competence and access to customers After separating the…
The last few days have brought a lot of changes in the biotechnological company Selvita. The company’s shareholders agreed to split the company and appoint four new members of the supervisory board of Ryvu Therapeutics. Selvita also announced the launch of phase I clinical trials of its acute myeloid leukemia drug (SEL120). Selvita separates Ryvu…
Dr. Setareh Shamsili became the new Chief Medical Officer at Selvita. This is another personnel change in the Polish biotechnology company. We have written about the previous ones here and here. From AxImmune to Selvita Dr. Shamsili has more than 20 years of experience in clinical oncology and drug development. Prior to joining Selvity, she…
Further personnel changes in the Polish biotechnology company Selvita. Dr. Tom Coulter has been appointed to the position of the director for integrated research and development projects. From Evotec to Selvita Dr. Tom Coulter will provide scientific support for Selvita’s drug discovery projects for external clients. The new director has been involved in the biotechnology…
On March 15, the Supervisory Board of Selvita SA decided to appoint Steffen Heeger to the position of a member of the Management Board of the company. The decision comes into force on 1 April 2019. Heeger will be responsible for clinical development as well as medical and regulatory issues related to oncology projects as…
According to a company report, Ryvu Therapeutics recorded a PLN 24.24m standalone net loss from continuing operations in the second quarter of 2021. This is higher than last year when the loss amounted to PLN 4.3m. The company also suffered a higher operating loss and EBITDA loss from continuing operations than in 2020. Ryvu Therapeutics…
Inno-Gene SA, a company operating in the area of medical diagnostics, has announced the commencement of activities aimed at transferring shares from NewConnect to the WSE main market. Currently, the issuer’s management board has started talks with brokerage houses and law firms which are to carry out the whole process. Purpose of the transition to…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.